New JAMA Study Confirms Treating Prostate Cancer Preferable To 'Watchful Waiting'

Endocare, Inc. (OTC Bulletin Board: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced today that a large study published in the Journal of the American Medical Association (JAMA) this month confirms that men with early prostate cancer should seriously consider all prostate cancer treatment options before choosing "watchful waiting" as a disease management approach. "Watchful waiting" is a concept that suggests patients can wait to see how their disease progresses before undergoing any curative treatments such as surgery or radiation.

The JAMA study published December 13, 2006, consisted of 44,630 men between the ages of 65 and 80 and found that those patients who chose to treat their prostate cancer were 30 percent less likely to die than those who waited. This suggests that all patients with localized disease regardless of age should consider definitive treatments rather than "watchful waiting." It is estimated that approximately 30,000 of the more than 225,000 men who are diagnosed with prostate cancer annually choose to wait rather than undergo treatment.

Endocare President, Chairman and CEO Craig T. Davenport noted, "This study offers further scientific evidence that 'watchful waiting' may not be the best option for many patients, particularly when there are effective, minimally invasive treatments like cryoablation available. Based on the results of the study, 'watchful waiting' patients should consider some kind of treatment. We believe cryoablation is an excellent option for many patients given its proven, long-term cancer control rate, low morbidity, and typically fast recovery time. Additionally, we believe cryoablation is a particularly good option for 'watchful waiting' patients who are not able to tolerate surgery or radiation, or for men with very small amounts of cancer in their prostate."

Cryoablation involves non-surgical freezing and destroying of the cancerous tumors using an Endocare Cryocare(R) System. Recently published 10-year data demonstrated that cryoablation is a viable, effective, safe, durable and many times preferable treatment option for prostate cancer.

About Endocare

Endocare, Inc. (http://www.endocare.com) is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver.

Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to: uncertainly regarding the future availability of funds under the Company's common stock purchase agreement with Fusion Capital and credit facility with Silicon Valley Bank; the risk that the Company's sale of common stock to Fusion Capital may cause dilution; the risk that sales of common stock by Fusion Capital may cause the market price of the Company's common stock to decline; the risk that, even despite the Company's financing arrangements with Fusion Capital and Silicon Valley Bank, the Company's independent auditor may issue a qualified opinion, to the effect that there is a substantial doubt about the Company's ability to continue as a going concern; uncertainty regarding the Company's ability to reach and maintain profitability; risks relating to the loss of the Company's largest customer or the reduction, delay or cancellation of orders from this customer; the risk that the Company may be required to make state and local tax payments that exceed the Company's settlement estimates; uncertainty regarding the Company's re-listing on a national stock exchange; uncertainty regarding the effects of effectuating the Company's proposed reverse stock split, in particular the possibility that the market may react negatively to the Company's effectuation of a reverse stock split; uncertainty regarding market acceptance of the Company's products; uncertainty of product development and the associated risks related to clinical trials; uncertainty relating to third party reimbursement; uncertainty regarding the ability to convince health care professionals and third party payers of the medical and economic benefits of the Company's products; the Company's limited sales, marketing and manufacturing experience; uncertainty regarding the ability to attract and retain key personnel; uncertainty regarding the ability to secure and protect intellectual property rights relating to the Company's technology; the rapid pace of technological change in the Company's industry; fluctuations in the Company's order levels; and the risk that the Company may be subject to civil or criminal liability if the Company violates the terms of its settlements with the SEC and the DOJ. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligation to revise, or update publicly, any forward-looking statements for any reason.

Endocare, Inc.
http://www.endocare.com